AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

45.26USD
1 Aug 2013
Price Change (% chg)

$-0.22 (-0.48%)
Prev Close
$45.48
Open
$45.14
Day's High
$45.90
Day's Low
$45.04
Volume
2,632,374
Avg. Vol
4,792,398
52-wk High
$48.00
52-wk Low
$32.51

ABBV.K

Chart for ABBV.K

About

AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidem... (more)

Overall

Beta: --
Market Cap (Mil.): $72,028.00
Shares Outstanding (Mil.): 1,583.73
Dividend: 0.40
Yield (%): 3.52

Financials

  ABBV.K Industry Sector
P/E (TTM): 13.98 37.93 37.76
EPS (TTM): 3.25 -- --
ROI: -- 19.48 18.76
ROE: -- 20.17 19.59
Search Stocks

Fast-growing Humira extends domination of AbbVie

- AbbVie Inc's reliance on its Humira arthritis drug became even more evident during the second quarter, when the product's sales jumped 12 percent and accounted for almost 56 percent of the U.S. drugmaker's revenue.

26 Jul 2013

UPDATE 2-Fast-growing Humira extends domination of AbbVie

July 26 - AbbVie Inc's reliance on its Humira arthritis drug became even more evident during the second quarter, when the product's sales jumped 12 percent and accounted for almost 56 percent of the U.S. drugmaker's revenue.

26 Jul 2013

FDA advisory panel votes against new use of AbbVie's Humira

- An advisory panel to the U.S. Food and Drug Administration voted against approving AbbVie Inc's rheumatoid arthritis drug Humira for treating an inflammatory disease of the spine.

23 Jul 2013

FDA advisory panel votes against new use of AbbVie's Humira

July 23 - An advisory panel to the U.S. Food and Drug Administration voted against approving AbbVie Inc's rheumatoid arthritis drug Humira for treating an inflammatory disease of the spine.

23 Jul 2013

BRIEF-Galapagos announces $50m extension to AbbVie deal

BRUSSELS, May 17 - Galapagos NV : * AbbVie and Galapagos extend GLPG0634 collaboration to include crohn's disease * Says AbbVie to pay Galapagos $50 million upon successful completion, expected

17 May 2013

Abbvie says Chief Scientific Officer John Leonard to retire

- AbbVie Inc's chief scientific officer will be retiring in the next few months and will be involved in the process of naming a successor, the pharmaceutical company said in a regulatory filing on Friday.

10 May 2013

Abbvie says Chief Scientific Officer John Leonard to retire

May 10 - AbbVie Inc's chief scientific officer will be retiring in the next few months and will be involved in the process of naming a successor, the pharmaceutical company said in a regulatory filing on Friday.

10 May 2013

AbbVie delivers on strong growth of Humira arthritis drug

- AbbVie Inc's quarterly profit rose 10 percent on surging sales of its Humira treatment for rheumatoid arthritis, and the company said it plans to launch several potentially lucrative new treatments for hepatitis C by early 2015.

26 Apr 2013

UPDATE 3-AbbVie delivers on strong growth of Humira arthritis drug

April 26 - AbbVie Inc's quarterly profit rose 10 percent on surging sales of its Humira treatment for rheumatoid arthritis, and the company said it plans to launch several potentially lucrative new treatments for hepatitis C by early 2015.

26 Apr 2013

AbbVie delivers on scorching Humira drug sales growth

- AbbVie Inc reported slightly better than expected quarterly results on Friday, fueled by surging sales of its Humira treatment for rheumatoid arthritis.

26 Apr 2013

Earnings vs. Estimates

Search Stocks